Sexual dysfunctions in breast cancer patients: evidence in context.

Autor:	Vizza R; 'Sapienza' University of Rome, Rome 00161, Italy., Capomolla EM; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy., Tosetto L; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy., Corrado G; Department of Woman and Child Health and Public Health, Woman Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome 00168, Italy., Bruno V; Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy., Chiofalo B; Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy., Di Lisa FS; Phase IV Clinical Studies Unit, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy., Filomeno L; Phase IV Clinical Studies Unit, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy., Pizzuti L; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy., Krasniqi E; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy., Sanguineti G; Department of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy., Villa A; Department of Experimental Medicine, 'Sapienza' University of Rome, Rome 00161, Italy., Giannini A; Department of Medical and Surgical Sciences and Translational Medicine, Sant'Andrea University Hospital, 'Sapienza' University of Rome, Rome 00189, Italy., Kayal R; Department of Radiology and Diagnostic Imaging, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy., Stranges V; 'Sapienza' University of Rome, Rome 00161, Italy., Tomao S; Department of Radiological, Oncological and Anatomo-pathological Sciences, 'Sapienza' University of Rome, Rome 00161, Italy., Botti C; Department of Surgery, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy., Tomao F; Department of Maternal and Child Health and Urological Sciences, 'Sapienza' University of Rome, Rome 00161, Italy., Barba M; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy., Vizza E; Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy., Ciliberto G; Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy., Vici P; Phase IV Clinical Studies Unit, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy.
Jazyk:	angličtina
Zdroj:	Sexual medicine reviews [Sex Med Rev] 2023 Jun 27; Vol. 11 (3), pp. 179-195.
DOI:	10.1093/sxmrev/qead006
Abstrakt:	Introduction: In breast cancer patients, endocrine therapy may exert a negative impact on sexual functioning in both genders, with potentially relevant consequences concerning quality of life and treatment adherence. The availability of effective interventions to maintain and/or restore sexual health in breast cancer patients is a key issue to a research agenda. Objectives: To summarize and critically discuss the most updated and qualitatively relevant literature on the therapeutic approach to sexual impairment in breast cancer patients, with a focus on patients treated with endocrine therapy. Methods: We searched PubMed from its inception to February 2022 for observational and intervention trials including participants with sexual dysfunctions. We were particularly interested in studies of breast cancer patients with sexual dysfunctions while undergoing endocrine therapy. We developed a search strategy with the aim of maximizing the number of articles considered for screening and potential inclusion. Results: Forty-five studies were selected: 3 observational and 42 intervention studies. Thirty-five studies were exclusively focused on female breast cancer populations. We could not identify studies exclusively focused on or also including male breast cancer patients. Overall, in female patients, the available armamentarium encompasses vaginal lubricants, moisturizers, estrogens, dehydroepiandrosterone, CO2 laser, ospemifene, and counseling. None of these interventions has been demonstrated to completely solve sexual dysfunctions when singularly considered. More favorable outcomes have come from the combination of different therapies. Conclusion: In female breast cancer, future research is oriented toward the gain of evidence on combined therapies and long-term data on safety issues on the most promising interventions. The lack of evidence on sexual disturbances in male breast cancer patients remains a major concern. (© The Author(s) 2023. Published by Oxford University Press on behalf of The International Society of Sexual Medicine.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu